摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-chloro-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine | 923595-50-0

中文名称
——
中文别名
——
英文名称
6-chloro-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine
英文别名
6-Chloro-3-(4-pyridinyl)imidazo[1,2-b]pyridazine;6-chloro-3-pyridin-4-ylimidazo[1,2-b]pyridazine
6-chloro-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine化学式
CAS
923595-50-0
化学式
C11H7ClN4
mdl
——
分子量
230.656
InChiKey
LMYGADXQYCPRJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.45±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] AMINOIMIDAZOPYRIDAZINES<br/>[FR] AMINOIMIDAZOPYRIDAZINES
    申请人:BAYER PHARMA AG
    公开号:WO2014076162A1
    公开(公告)日:2014-05-22
    The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)的氨基取代咪唑吡啶化合物,其中A、R1、R2、R3、R4和n如权利要求中所定义,以及制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分组合使用时,用于治疗或预防过度增殖和/或血管生成障碍的疾病。
  • [EN] INHIBITORS OF LIN28 AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LIN28 ET LEURS MÉTHODES D'UTILISATION
    申请人:UNIV CALIFORNIA
    公开号:WO2021126779A1
    公开(公告)日:2021-06-24
    The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cancers.
    本公开涉及公式(I)的化合物以及包含相同化合物的组合物。进一步地,本公开还涉及治疗癌症的方法。
  • [EN] HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES<br/>[FR] HÉTÉROCYCLYLAMINOIMIDAZOPYRIDAZINES
    申请人:BAYER IP GMBH
    公开号:WO2012175591A1
    公开(公告)日:2012-12-27
    The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)的杂环氨基咪唑吡啶化合物,其中A、R1、R2、R3和R4如权利要求中所定义,涉及制备所述化合物的方法,包括所述化合物的药物组合物和配方,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一活性成分或与其他活性成分组合使用,治疗或预防过度增殖和/或血管生成障碍的疾病。
  • 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF
    申请人:Garcia Antonio Almario
    公开号:US20110312934A1
    公开(公告)日:2011-12-22
    The invention relates to 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives of the general formula (I) where: R 2 is a C 1-6 -alkyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-4 -alkyl, C 1-4 -alkyloxy-C-M-alkyl, C 3-7 -cycloalkyloxy-C 1-4 -alkyl>C 3-7 -cycloalkyl-C 1-4 -alkyloxy-C 1-4 -alkyl, hydroxy-C 1-6 -alkyl, C 1-4 -fluoroalkyl group; R 3 is a hydrogen atom or a substituent selected from halogen atoms and the C 1-3 alkyl, —NR 4 R 5 , hydroxyl or C 1-4 alkyloxy groups; A is a C 1-7 -alkylene group optionally substituted by one or two R a groups; B is a C 1-7 -alkylene group optionally substituted by one or two R b groups; L is either a nitrogen atom optionally substituted by an R c or R d group or a carbon atom substituted by an R e1 group and an R d group or by two R e2 groups; Rd is a group selected from a hydrogen atom or a C 1-6 -alkyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-6 -alkyl, C 1-6 -alkylthio-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1-6 -alkyl, C 1-6 -fluoroalkyl, hydroxy-C 1-6 -alkyl group; R f is a C 1-6 -alkyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1-6 -alkyl, C 3-7 -cycloalkyloxy-C 1-4 -alkyl, C 3-7 -cycloalkyl-C 1-4 -alkyloxy-C 1-4 -alkyl, hydroxy-C 1-6 -allyl, C 1-6 -fluoroalkyl or benzyl group. The invention also relates to a method for preparing same and to the therapeutic application thereof.
    该发明涉及通式(I)的2-烷基-6-环氨基-3-(吡啶-4-基)咪唑并[1,2-b]吡啶嗪衍生物,其中:R2是C1-6-烷基,C3-7-环烷基,C3-7-环烷基-C1-4-烷基,C1-4-烷氧基-C-M-烷基,C3-7-环烷氧基-C1-4-烷基>C3-7-环烷基-C1-4-烷氧基-C1-4-烷基,羟基-C1-6-烷基,C1-4-氟烷基;R3是氢原子或卤素原子和C1-3烷基,—NR4R5,羟基或C1-4烷氧基中选择的取代基;A是C1-7-烷基,可选地被一个或两个Ra基团取代;B是C1-7-烷基,可选地被一个或两个Rb基团取代;L是氮原子,可选地被Rc或Rd基团取代,或是碳原子,被Re1基团和Rd基团或两个Re2基团取代;Rd是选择自氢原子或C1-6-烷基,C3-7-环烷基,C3-7-环烷基-C1-6-烷基,C1-6-烷硫基-C1-6-烷基,C1-6-烷氧基-C1-6-烷基,C1-6-氟烷基,羟基-C1-6-烷基的基团;Rf是C1-6-烷基,C3-7-环烷基,C3-7-环烷基-C1-6-烷基,C1-6-烷氧基-C1-6-烷基,C3-7-环烷氧基-C1-4-烷基,C3-7-环烷基-C1-4-烷氧基-C1-4-烷基,羟基-C1-6-烯丙基,C1-6-氟烷基或苄基。该发明还涉及其制备方法和治疗应用。
  • FUSED HETEROCYCLES AS LCK INHIBITORS
    申请人:Nakai Kazuo
    公开号:US20100216798A1
    公开(公告)日:2010-08-26
    There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; —X— is —N(R 1 )— or the like, —R 1 represents hydrogen or the like, -A- represents bond or the like, —R 2 is cycloalkyl, aryl or the like, -E- is bond or the like, —R 3 is aryl, aromatic heterocycle or the like, —R 4 , —R 5 and —R 6 are the same or different, each being hydrogen or the like.]
    提供了一种公式(I)所表示的咪唑吡啶嗪或吡唑嘧啶衍生物的熔合杂环,其具有出色的Lck抑制活性,可用于药物,特别是免疫抑制剂。[其中Y和Z中的一个是碳原子,另一个是氮原子;—X—是—N(R1)—或类似物,—R1表示氢或类似物,-A-表示键或类似物,—R2是环烷基,芳基或类似物,-E-是键或类似物,—R3是芳基,芳香杂环或类似物,—R4,—R5和—R6相同或不同,每个都是氢或类似物。]
查看更多